A 16-year-old boy is brought by his parents to his primary care physician because of a decline in school performance, which began at least three years earlier and has become more severe in the past year. He reports boredom, a lack of enjoyment and motivation, poor self-esteem, a feeling of hopelessness, difficulty sleeping, poor concentration, and passive thoughts of suicide without a plan or intent. How should he be treated?
The Clinical Problem
This patient presents with a clear picture of major depression, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, of the American Psychiatric Association. In children and adolescents, depression is not always characterized by sadness, but instead by irritability, boredom, or an inability to experience pleasure. Depression is a chronic, recurrent, and often familial illness that frequently first occurs in childhood or adolescence. Any child can be sad, but depression is characterized by a persistent irritable, sad, or bored mood and difficulty with familial relationships, school, and work. In the absence of treatment, a major depressive episode lasts an average of eight months. The risk of recurrence is approximately 40 percent at two years and 72 percent at five years. Longer depressive episodes occur in patients who have a dysthymic disorder (a milder, but chronic and insidious form of depression) that gradually evolves into major depression. More prolonged episodes are also associated with coexisting psychiatric conditions, parental depression, and parent–child discord.
At least 20 percent of those with early-onset depressive disorders (those beginning in childhood or adolescence) are at risk for bipolar disorder, particularly if they have a family history of bipolar disorder, psychotic symptoms, or a manic response to antidepressant treatment. Bipolar disorder is characterized by depressive episodes that alternate with periods of mania, defined by a decreased need for sleep, increased energy, grandiosity, euphoria, and an increased propensity for risk-taking behavior. Often in children and adolescents, mania and depression occur as “mixed states,” in which the lability of mania is combined with depression, or there is rapid cycling between depression and mania over a period of days or even hours.
Suicidal behavior is closely associated with depression. Risk factors for suicide during a depressive episode include chronic depression, coexisting substance abuse, impulsivity and aggression, a history of physical or sexual abuse, same-sex attraction and sexual activity, a personal or family history of a suicide attempt, and access to an effective means of suicide, such as a gun. Girls are more likely to attempt suicide, and boys to complete suicide. Among adolescents, the annual rate of suicide attempts requiring medical attention is 2.6 percent. Suicide is much rarer. Among 15-to-19-year-olds, the rates in 1998 were 14.6 per 100,000 in boys and 2.9 per 100,000 in girls.
Depression is present in about 1 percent of children and 5 percent of adolescents at any given time. Before puberty, boys and girls are at equal risk for depression, whereas after the onset of puberty, the rate of depression is about twice as high in girls. Having a parent with a history of depression increases a child’s risk of a depressive episode by a factor of 2 to 4. Anxiety, particularly social phobia, may be a precursor of depression. Depression is more common in persons with chronic illnesses such as diabetes and epilepsy and after stressful life events such as the loss of a friend, parent, or sibling. Parent–child discord, abuse, and neglect increase the risk of depression. Alterations in central serotonergic and noradrenergic neurotransmission are associated with and may antedate childhood depression. Screening instruments are available at no or minimal cost that are both sensitive and specific for depression, such as the Center for Epidemiological Studies–Depression Scale (available at www. moodykids.org) and the Mood and Feelings Questionnaire (available at devepi.mc.duke.edu/mfq.html).
Strategies and Evidence
Medical illness should be ruled out in patients presenting with depression. For example, anemia, mononucleosis, hypothyroidism or hyperthyroidism, inflammatory bowel disease, and collagen vascular disease may cause symptoms that overlap with depression. Social functioning should be assessed in order to determine the intensity of treatment. Inpatient care is required if the patient is acutely suicidal, has substance dependence, or is psychotic, manic, or so functionally impaired that outpatient treatment cannot proceed effectively. A patient’s personal and family history should be evaluated to determine whether there is a history of mania, since approaches to treatment differ for bipolar and unipolar depression. Clinicians should also ascertain whether the patient has suicidal ideation and intent, a personal or family history of suicide attempts, and access to lethal agents such as firearms. Finally, the patient’s home environment should be assessed for sources of stress, including parental depression and the presence of discord, abuse, or neglect, since these factors result in a poor outcome.
Four components are key to the initiation of treatment. First, the parents and patient should receive education about depressive illness and its symptoms, causes, probable course, and treatment. A clear treatment contract, which reflects the confidentiality afforded the adolescent patient and its limits, helps to facilitate a trusting relationship among the adolescent, his or her family, and the clinician. Viewing depression as an illness like diabetes or hypertension helps families to take charge of its management, avoid placing blame, and set reasonable expectations regarding a treatment response. Second, identification and mitigation of hopelessness, especially about treatment, can be accomplished in part through education and a discussion of expectations. Hopelessness in depressed patients predicts withdrawal from treatment and suicidal behavior.
Third, a no-suicide contract should be established. This is an oral agreement among the patient, his or her family, and the clinician regarding the way in which suicidal thoughts and urges are to be handled. The patient agrees to contact a responsible adult and, ultimately, the clinician if he or she feels suicidal. The process of developing the no-suicide contract tests the ability of the adolescent and his or her family to solve problems and form a relationship with the treating clinician. The precipitants of previous suicidal behavior are identified, and a coping plan is agreed on by the patient and his or her parents. In one study, this approach reduced the number of suicide attempts among runaway youths who were at high risk for a suicide attempt, but this method has not been subjected to rigorous evaluation. Fourth, firearms should be secured or removed from the patient’s home, because their presence is a risk factor for suicide.
Uncomplicated cases of adolescent depression can be managed by many primary care physicians, if they have adequate training, experience, and consultative support. However, depression that is complicated by a coexisting condition (e.g., attention-deficit–hyperactivity disorder or substance abuse), bipolarity, suicide attempts, psychosis, multiple episodes of depression, or treatment resistance is best handled by a child psychiatrist.
Two types of clinical interventions have established efficacy — antidepressant treatment and certain forms of psychotherapy. These two types of treatment are currently being compared in a large clinical trial funded by the National Institute of Mental Health. Available studies of apparently comparable subjects show similar rates of clinical response to either psychotherapy or medication. Therefore, either approach can be empirically justified, with a choice between medication and psychotherapy based on clinicians’ and patients’ preference.
Selective serotonin-reuptake inhibitors (SSRIs) are the most commonly used treatment for adolescent depression, because of the proven efficacy of fluoxetine, citalopram, and paroxetine in placebo-controlled trials, with a response rate of approximately 60 percent and a favorable side-effect profile. Tricyclic antidepressants are no longer considered first-line agents for adolescent depression, since controlled studies found them to be no better than placebo, and the risk of a fatal overdose is much greater than for SSRIs.
The recommended practice for children and adolescents is to start at half the usual dose of an SSRI (e.g., 10 mg of fluoxetine, citalopram, or paroxetine per day) for one week to help the patient adjust to any side effects and then increase the dose to the equivalent of 20 mg of fluoxetine for another three weeks. The dose can be increased at intervals of no less than four weeks, since it takes at least four weeks at steady state to determine whether a given dose will be helpful.
Because children and adolescents metabolize SSRIs more rapidly than adults, they may often require doses above the equivalent of 20 mg of fluoxetine to attain a clinical response. In one report, 71 percent of patients who initially had no response to a 20-mg dose of fluoxetine had a response to an increased dose (40 to 60 mg), as compared with 36 percent of those who continued to receive the 20-mg dose. Once an adequate clinical response has been achieved, treatment should be continued for at least six months to one year, to reduce the risk of relapse.
The most common side effects of SSRIs are nausea, loss of appetite, and sedation. Occasionally, SSRIs cause agitation, even difficulty sitting still. This side effect usually necessitates withdrawal of the SSRI and prescription of an alternative SSRI or another class of antidepressant.
Eight to 16 sessions of cognitive behavioral therapy (over a period of three to four months) have been shown to be more efficacious than alternative psychotherapies (i.e., family, supportive, and relaxation therapies) for adolescent depression. In this approach, patients learn to increase pleasurable activities, acquire skills to improve interpersonal effectiveness, and identify and modify dysfunctional and self-defeating patterns of cognition that can lead to depressed mood. Another type of brief psychotherapy, interpersonal therapy, has been shown to be efficacious for adolescent depression in two clinical trials; in one it was compared with supportive clinical management, and in the other patients were compared with controls on a waiting list for treatment. In interpersonal therapy, adolescents learn to cope with interpersonal difficulties such as loss of relationships, discord, and role transitions that are often associated with depression. Psychotherapy may need to be continued on a monthly basis for an additional six months to decrease the risk of relapse.
If a patient has no response to cognitive behavioral therapy or interpersonal therapy after six to eight weeks, accepted guidelines recommend adding an SSRI to the treatment regimen. Conversely, if a patient has no response to an SSRI, then adding cognitive behavioral therapy or interpersonal therapy is also supported by the literature on empirical treatment in adults. Although it is logical to posit that treating parental depression and reducing parent–child discord would enhance the treatment response in depressed adolescents, this has not been proved. Patients with chronic depression (lasting more than one year) should probably receive both medication and psychotherapy.
Before concluding that a patient has had no response to an SSRI, it is vital to ensure that the dose and adherence are adequate. Switching to another SSRI will result in an acceptable clinical response about 50 percent of the time, according to open trials in adults. Other approaches for which there is empirical support in adults are to add lithium to the regimen or to switch to an alternative antidepressant, such as venlafaxine.
Treatment of Coexisting Conditions
Adolescents with depression who also have attention-deficit–hyperactivity disorder may often have no response to SSRIs alone. An open trial suggests that bupropion, an antidepressant with dopaminergic- and noradrenergic-agonist properties, may be efficacious in treating both depression and attention-deficit–hyperactivity disorder. Substance abuse often complicates mood disorder in adolescence. Treatment of patients with both depression and alcohol abuse with SSRIs is considered safe and has improved depressive symptoms and reduced alcohol and substance abuse in randomized clinical trials of adults and in open-label studies in adolescents. However, some of these adolescents may require specialized treatment for substance abuse.
Treatment of Bipolar Depression
Because of the relatively high risk of bipolar disorder in patients with early-onset depression, patients and their families should be taught to identify the symptoms of mania and the importance of quickly contacting the treating clinician if these symptoms emerge. Treatment of bipolar disorder is beyond the scope of this review, but it would necessitate decreasing or stopping the antidepressant medication and initiating treatment with a mood stabilizer, such as lithium or divalproex. In adults, bupropion may be less likely than other antidepressants to result in mania.
Psychosis has been reported in up to 30 percent of patients with childhood-onset depression and is often a harbinger of bipolar disorder. On the basis of studies in adults, it is recommended that adolescent patients with psychotic depression be treated with a combination of neuroleptic agents and antidepressants.
Limiting Access to Lethal Agents
Families of depressed and suicidal patients should be warned about the risks of having guns in the home and should be asked to remove them. However, most families will not comply with this request when asked.36 Compliance may be improved by communicating directly with the gun owner and suggesting a range of options, from securing the gun to removing it.
Fortunately, overdoses of SSRIs are rarely toxic. However, overdoses of other medications, such as lithium, can be fatal, and access to these medications should be restricted and regulated by the patient’s parents.
Areas of Uncertainty
Areas of uncertainty in the management of adolescent depression include specific indications for antidepressant medication and psychotherapy, alone or in combination; the optimal duration of continuation and maintenance treatment, management of treatment-resistant depression, bipolar depression, depression in combination with attention-deficit–hyperactivity disorder, or substance abuse and psychotic depression; and the optimal approach to convincing families to secure or remove firearms.
Because most clinical trials of depression in adults have excluded suicidal patients, the optimal approach to the treatment of these patients remains unclear. Interventions that may reduce the risk of suicidal behavior include brief psychotherapy that targets difficulties with anger, hopelessness, and interpersonal skills — problems that often contribute to suicidal behavior in adolescents.
The American Academy of Child and Adolescent Psychiatry has published practice guidelines for handling depression and suicidal behavior in children and adolescents that are reflected in our recommendations. Algorithms for dealing with depression in combination with other disorders and treatment-resistant depression have also been published, but they still need rigorous evaluation.
Conclusions and Recommendations
Adolescent depression is a chronic, recurrent, and serious illness associated with substantial morbidity and mortality. It is also an eminently treatable condition that responds to SSRIs and specific psychotherapies (cognitive behavioral therapy and interpersonal therapy). For an adolescent like the boy described in the vignette, who has worsening chronic depression, a combination of medication and psychotherapy may provide the best chance for complete recovery.
Optimal treatment with SSRIs requires the use of an adequate dose, and the dose may need to be higher than that used in adults. If the adolescent in the vignette had no response to the usual dose of an SSRI in four weeks despite good compliance, we would increase the dose before considering the agent to be ineffective. If treatment with an SSRI is effective, it should be continued for at least six months after the occurrence of symptomatic relief to reduce the risk of relapse.
It is important to determine whether a patient can comply with a no-suicide contract and to encourage his or her parents to remove any firearms from the home. Patient and family education is critical. An important goal of education is to minimize the patient’s feelings of hopelessness, since hopeless patients are more likely to stop treatment and to attempt suicide. Long-term follow-up is critical to identify and treat relapse if it occurs.
Supported by Services for Teens at Risk (Commonwealth of Pennsylvania) and by grants (MH 55123, MH 70008, and MH 56612) from the National Institute of Mental Health.
From the Western Psychiatric Institute and Clinic, Division of Child and Adolescent Psychiatry, University of Pittsburgh Medical Center, Pittsburgh.
1. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
2. Birmaher B, Ryan ND, Williamson DE, et al. Child and adolescent depression: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996;35:1427-1439.
3. Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001;158:125-127.
4. Geller B, Zimerman B, Williams M, et al. Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000;10:157-164.
5. Brent DA. Mood disorders and suicide. In: Green M, Haggerty RJ, eds. Ambulatory pediatrics. 5th ed. Philadelphia: W.B. Saunders, 1999:447-54.
6. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. J Am Acad Child Adolesc Psychiatry 2001;40:Suppl:24S-51S.
7. Beardslee WR, Versage EM, Gladstone TRG. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998;37:1134-1141.
8. Stein MB, Fuetsch M, Muller N, Hofler M, Lieb R, Wittchen HU. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry 2001;58:251-256.
9. Dierker LC, Albano AM, Clarke GN, et al. Screening for anxiety and depression in early adolescence. J Am Acad Child Adolesc Psychiatry 2001;40:929-936.
10. Angold A, Costello EJ, Messer SC, Pickles A, Winder F, Silver D. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. Int J Methods Psychiatr Res 1995;5:237-49.
11. Brent DA, Kolko D, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998;37:906-914.
12. Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000;57:29-36.
13. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998;7:32-39.
14. Rotheram MJ. Evaluation of imminent danger for suicide among youth. Am J Orthopsychiatry 1987;57:102-110.
15. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in depressed children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-1037.
16. Keller M, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled study. J Am Acad Child Adolesc Psychiatry 2001;40:762-772.
17. Hazell P, O’Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995;310:897-901.
18. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-3445.
19. Axelson D, Perel J, Birmaher B, Rudolph G, Nuss S, Brent D. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry.
David A. Brent, M.D., and Boris Birmaher, M.D.
The New England Journal of Medicine